New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
Subscribe To Our Newsletter & Stay Updated
